CoChat

The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial

Open access

Published version of a preprint

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; 3 of the 26 sources its claims cite were checked for support.

Abstract

Background The prevalence of depressive and anxiety symptoms in patients with COVID-19 is higher than usual. Previous studies have shown that there are drug-to-drug interactions between antiretroviral drugs and antidepressants. Therefore, an effective and safe treatment method was needed. Cognitive behavioral therapy (CBT) is the first-line psychological therapy in clinical treatment. Computerized CBT (cCBT) was proven to be an effective alternative to CBT and does not require face-to-face therapy between a therapist and the patient, which suited the COVID-19 pandemic response. Objective This study aims to evaluate the efficacy of the cCBT program we developed in improving depressive and anxiety symptoms among patients with COVID-19. Methods We customized a cCBT program focused on improving depressive and anxiety symptoms among patients with COVID-19, and then, we assessed its effectiveness. Screening was based on symptoms of depression or anxiety for patients who scored ≥7 on the Hamilton Depression Rating Scale (HAMD17) or the Hamilton Anxiety Scale (HAMA). A total of 252 patients with COVID-19 at five sites were randomized into two groups: cCBT + treatment as usual (TAU; n=126) and TAU without cCBT (n=126). The cCBT + TAU group received the cCBT intervention program for 1 week. The primary efficacy measures were the HAMD17 and HAMA scores. The secondary outcome measures were the Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), and Athens Insomnia Scale (AIS). Assessments were carried out pre- and postintervention. The patients’ symptoms of anxiety and depression in one of the centers were assessed again within 1 month after the postintervention assessment. Results The cCBT + TAU group displayed a significantly decreased score on the HAMD17, HAMA, SDS, SAS, and AIS after the intervention compared to the TAU group (all P<.001). A mixed-effects repeated measures model revealed significant improvement in symptoms of depression (HAMD17 and SDS scores, both P<.001), anxiety (HAMA and SAS scores, both P<.001), and insomnia (AIS score, P=.002) during the postintervention and follow-up periods in the cCBT + TAU group. Additionally, the improvement of insomnia among females (P=.14) and those with middle school education (P=.48) in the cCBT + TAU group showed no significant differences when compared to the TAU group. Conclusions The findings of this study suggest that the cCBT program we developed was an effective nonpharmacological treatment for symptoms of anxiety, depression, and insomnia among patients with COVID-19. Further research is warranted to investigate the long-term effects of cCBT for symptoms of anxiety, depression, and insomnia in patients with COVID-19. Trial Registration Chinese Clinical Trial Registry ChiCTR2000030084; http://www.chictr.org.cn/showprojen.aspx?proj=49952

Overview

CoChat Summary

## TL;DR

This multicenter randomized controlled trial found that a 1-week computerized CBT program added to treatment as usual reduced depressive, anxiety, and insomnia symptoms in patients with COVID-19 compared with treatment as usual alone. The benefits were seen immediately postintervention and were still present at 1-month follow-up in the subset assessed.

## Key findings

  • Among 252 analyzable patients with COVID-19 randomized 1:1 to cCBT + TAU (n=126) or TAU (n=126), the cCBT + TAU group had significantly lower postintervention scores on all primary and secondary outcomes: HAMD17, HAMA, SDS, SAS, and AIS, all P<.001.
  • In the repeated-measures analysis, the cCBT + TAU group showed significant improvement over postintervention and follow-up in depression (HAMD17 and SDS, both P<.001), anxiety (HAMA and SAS, both P<.001), and insomnia (AIS, P=.002).
  • At 1-month follow-up, the interaction between group and period was significant for all five scales (all P<.001), and post hoc tests showed significant reductions from baseline in the cCBT + TAU group for all five scores (all P<.05, Bonferroni-adjusted).
  • Subgroup analyses found no significant between-group improvement in insomnia for females (P=.14) or for patients with middle school education (P=.48).

## Methods

  • Prospective, multicenter, nonblinded, two-arm, parallel-group randomized controlled trial conducted at five hospitals in China from March 2020 to June 2020.
  • Eligible participants were adults 18–75 years with mild/common COVID-19 and mild to moderate depressive or anxiety symptoms, defined as HAMD17 ≥7 or HAMA ≥7; 252 participants were analyzed after screening.
  • Participants were randomized 1:1 to 1 week of cCBT + TAU or TAU alone; main analyses used t tests, subgroup analyses, and a mixed-effects model for repeated measures (MMRM) with Bonferroni post hoc testing.

## Limitations

  • The paper states the trial was nonblinded, and says this, together with multiple outcomes, increased the risk of type I error.
  • The paper states the sample sizes were relatively small and the follow-up time was relatively short.
  • The paper states it did not account for more confounding factors such as drug side effects and related adversity.
  • Evident from the text: the 1-month follow-up was done in only one center, so longer-term generalizability is limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2196/26883

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Figure 1 Flow diagram of the study. cCBT: computerized cognitive behavioral therapy; TAU: treatment as usual.
Figure 1 Flow diagram of the study. cCBT: computerized cognitive behavioral therapy; TAU: treatment as usual.CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 0 Not valid · 16 Not checked · 32 Own results and interpretations

20 more claims

Create a free account to see all 50 claims and to verify the 23 references still open.

See all claims — free account
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 14

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 61 references

Research works printed but not linked: 5

  1. Bisson, JI, 2010, BMJ Clin Evid, 2010, 1005
  2. Li, CE, 2006, Adolescence, 41, 409
  3. Yuan, M, 2016, Sichuan Da Xue Xue Bao Yi Xue Ban, 47, 898
  4. 10.13798/j.issn.1009-153x.2020.08.011 · doi:10.13798/j.issn.1009-153x.2020.08.011
  5. 10.3969/j.issn.2095-8552.2020.11.028 · doi:10.3969/j.issn.2095-8552.2020.11.028

Cited by

See all 185

Metadata

Authors
Liu, Z., Qiao, D., Xu, Y., Zhao, W., Yang, Y., Wen, D., Li, X., Nie, X., Dong, Y., Tang, S., Jiang, Y., Wang, Y., Zhao, J., & Xu, Y.
Affiliations
  • Shanxi Medical University (CN)
  • Chongqing Public Health Medical Center (CN)
  • Chongqing University (CN)
Corresponding author
Xu, Yong
Venue
Journal of Medical Internet Research
Published
2021-05-14
Volume
23
Issue
5
Pages
e26883
ISSN
1438-8871 (ISSN-L)
OpenAlex
W3159534035
Cited by
169
References
61
Citations by year
2026: 9 · 2025: 40 · 2024: 29 · 2023: 51 · 2022: 31 · 2021: 9
FWCI
26.65
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Medical Internet Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81601193)
  • Shanxi Scholarship Council of China (2015-100)
  • Shanxi Medical University (YC1409)
  • Shanxi Province Science Foundation for Youths (2015021204)
Topics
  • Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
Keywords
computerized cognitive behavioral therapy, COVID-19 pandemic, depressive symptoms, anxiety symptoms, insomnia, psychological intervention, antiretroviral drugs, antidepressant drug interactions, usual care, Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Zung Self-Rating Depression Scale, Self-Rating Anxiety Scale, Athens Insomnia Scale, sex differences, educational attainment, follow-up outcomes, COVID-19 patients
MeSH terms
COVID-19, SARS-CoV-2, Adult, Anxiety, Depression, Female, Humans, Male, Prospective Studies, Cognitive Behavioral Therapy, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.